Progress of venetoclax in treatment of hematologic malignancies
10.3760/cma.j.cn115356-20220410-00104
- VernacularTitle:维奈克拉治疗血液系统恶性肿瘤的研究进展
- Author:
Qiaoyu ZHANG
1
;
Xin DU
Author Information
1. 深圳市第二人民医院血液内科，深圳 518035
- Keywords:
Hematologic neoplasms;
Venetoclax;
Drug tolerance;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2023;32(4):253-256
- CountryChina
- Language:Chinese
-
Abstract:
The anti-apoptotic protein bcl-2, a key regulator of the intrinsic apoptotic pathway, is frequently overexpressed in cells of hematologic malignancies, and the small molecule inhibitor venetoclax that targets this apoptotic pathway has shown promising efficacy in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. The survival and prognosis of patients with acute myeloid leukemia who are of advanced age or who are unsuitable for strong induction chemotherapy because of comorbidities also have significantly improved, but some patients develop progressive drug resistance during the course of venetoclax treatment, which affects the efficacy of medical therapy. This article reviews the action mechanism, therapeutic progress and resistance mechanism of venetoclax in hematologic malignancies.
